Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership combines Myriad's advanced laboratory capabilities in the U.S. with SOPHiA GENETICS' broad, decentralized network of over 800 connected institutions in more than 70 countries.
The initial focus of the collaboration will be on developing the MSK-ACCESS® powered with SOPHiA DDM™ liquid biopsy application into a CDx. This aims to expand patient access to high-quality tumor profiling tests and advance personalized healthcare at scale.
Under the agreement, Myriad will pursue regulatory submissions in the U.S., while SOPHiA GENETICS will manage regulatory submissions outside of the U.S., with both companies collaborating on development activities. This innovative hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally, laying the foundation for a new model in companion diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.